Induced Pluripotent Stem Cells
Accelerating the development of iPSC-derived immunotherapies and regenerative medicines
Setting a New Standard in iPSCs
Developing iPSC-Derived Allogeneic Immune Therapies
In collaboration with George Daley, M.D, Ph.D. and Boston Children’s Hospital, ElevateBio established a new company to develop off-the-shelf immune therapies derived from induced pluripotent stem cells (iPSCs). The company is founded upon a novel differentiation process that develops iPSCs into mature immune cells, which was detailed in a peer-reviewed publication in Cell Stem Cell. This new company is enabled by our iPSC and gene editing technologies and scale-up manufacturing capabilities to develop a broad pipeline of iPSC-derived therapies.
Our Integrated Technology Platforms Fueling the Discoveries of Tomorrow
RNA, Cell, Protein, and Vector Engineering
We have centralized RNA, cell, protein, and vector engineering to improve productivity and scalability and to ensure external partners and internal programs have access to the necessary tools to build novel therapies.
Our Therapeutic Approaches
We are enabling the development of a range of ex vivo and in vivo cell and gene therapies, leveraging our in-house capabilities and expertise to design and develop an array of modalities.
We help our partners scale new heights in cell and gene therapies by providing a full spectrum of viral vector and cell therapy capabilities to bring concepts to commercialization.
Partner with ElevateBio®
Wherever you are in your cell and gene therapy product lifecycle, we can strengthen and accelerate the development of your transformative therapies with our enabling technologies unmatched manufacturing capabilities.
// Work with us